Emerging modalities, like viral vectors, represent a part of one of the fastest growing therapeutic segments, gene therapy, and they are transforming the lives of patients through cures for disease and, more recently, to the fight against the COVID-19 pandemic. The complexity of this emerging class of therapies is related to their own complexity and limited precedence. This presentation will describe how lessons learned from traditional biopharmaceuticals can be applied to this new field.
Join Dr. Colette Quinn as she shares compliant, consistent and transferable techniques for the characterization and surveillance of viral vectors.
Key learning objectives:
- Growth and optimism supporting viral vector therapies and vaccines
- How compliant methods of protein characterization can be transferred to this space
- Techniques for obtaining more consistent results
Who should be present:
- Biopharmaceutical organizations, CXOs and research institutes
- Analytical scientists supporting biologics development, R&D, BMR discovery, structural biology, higher order structure analysis
- Laboratory managers, directors and vice-presidents in charge of protein characterization, structural biologist
Certificate of attendance
All webinar participants can request a certificate of attendance, including a summary of learning outcomes, for continuing education purposes.